BridgeMD
Evaluation of the clinical implementation of biofilm susceptibility to antibiotics using Minimum Biofilm Eradication Concentration (MBEC) in addition to Minimum Inhibitory Concentration (MIC) to guide the treatment of periprosthetic joint infections; a prospective randomized clinical trial
EU CTIS ID: 2024-518350-17-00
What this study is testing
A prospective comparative study of antibiotic treatment regimens for PJI guided by MIC or MBEC combined with MIC, and how it affects infection resolution, drug tolerability and relapse strain resistance patterns
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- First-time PJI in hip or knee according to Musculoskeletal Infection Society (MSIS) definitions; first DAIR (debridement, antibiotics and implant retention); mono-microbial staphylococcal infection; 14 days of intravenous treatment with either cloxacillin or vancomycin; standardized administration of local antibiotics.
You likely can't join if
- Allergy/previous toxic event/unacceptable drug interaction to most effective antibiotic combination according to either MIC or MBEC; severe drug interactions to MBEC-guided compound. Pregnancy and women of childbearing potential (WOCBP).
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.